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Abstract
Background: Among people living with HIV (PLWH), the prevalence of non-HIV related co-morbidities is increasing.
Aim of the present study is to describe co-morbidity and multi-morbidity, their clustering mode and the potential
disease-disease interactions in a cohort of Italian HIV patients.
Methods: Cross-sectional analysis conducted by the Coordinamento Italiano per lo Studio di Allergia e Infezioni da
HIV (CISAI) on adult subjects attending HIV-outpatient facilities. Non-HIV co-morbidities included: cardiovascular
disease, diabetes mellitus, hypertension, oncologic diseases, osteoporosis, probable case of chronic obstructive
pulmonary disease (COPD), hepatitis C virus (HCV) infection, psychiatric illness, kidney disease. Multi-morbidity was
defined as the presence of two or more co-morbidities.
Results: One thousand and eighty-seven patients were enrolled in the study (mean age 47.9 ± 10.8). One hundred-
ninety patients (17.5%) had no co-morbidity, whereas 285 (26.2%) had one condition and 612 (56.3%) were multi-
morbid. The most recurrent associations were: 1) dyslipidemia + hypertension (237, 21.8%); 2) dyslipidemia + COPD
(188, 17.3%); 3) COPD + HCV-Ab+ (141, 12.9%). Multi-morbidity was associated with older age, higher body mass
index, current and former smoking, CDC stage C and longer ART duration.
Conclusions: More than 50% of PLHW were multi-morbid and about 30% had three or more concurrent
comorbidities. The identification of common patterns of comorbidities address the combined risks of multiple drug
and disease-disease interactions.
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Background
In recent years, the prevalence of co-morbidities among
Persons Living With HIV infection (PLWH) increased,
as a consequence of aging, chronic inflammation, systemic
immune activation, and long-term exposure to the com-
bination antiretroviral therapy (ART) [1–3]. For this rea-
son, PLWH had an increased use of non-antiretroviral
drugs as compared to the general population [4]. Higher
attention was recently paid to the treatment and the
consequences of the main co-morbidities: cardiovascular
[5], renal [6], neurocognitive [7, 8], bone disease [9], non-
AIDS related cancers [10].
Managing patients with multiple chronic co-morbidities
is more challenging than managing those with a single
condition. Current HIV guidelines [11] recommend close
monitoring of cardiovascular, metabolic, hepatic, renal,
and bone health. Investigating common patterns and
disease-disease interactions between co-morbidities could
support the development of intervention models, improve
the management of multi-morbid patients, and provide
indication for prevention of multiple comorbidities in
PLWH [12].
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An important issue is how the co-morbidities associate
among them (i.e. clusterization of co-morbidities), be-
cause of the implications in terms of disease-disease and
drug-drug interactions. In fact, if the therapy recom-
mended for one disease is contraindicated in presence of
a concurrent medical condition, the usefulness of clinical
practice guidelines is limited. In such a scenario, evidence-
based treatment guidelines, designed for single diseases,
can lead to serious therapeutic conflicts, due to disease-
disease and drug-drug interactions. Management of multi-
morbid patients is challenging, especially in emergency
conditions.
To provide information on the issue, this cross-sectional
study aimed at describing the pattern of co-morbidity and
multi-morbidity in age class, their clustering mode and
the potential disease-disease interactions in a group of
PLWH referring to a network of Italian Infectious
Diseases centers.
Methods
This study is a cross-sectional analysis of baseline data
from a cohort study, conducted by the Coordinamento
Italiano per lo Studio di Allergia e Infezioni da HIV
(CISAI). Patients analyzed were enrolled in the STOPS-
HIV Study cohort, from July 2014 to December 2016:
this is an ongoing cohort study including adult (≥18
years old) PLWH attending the participating centers.
The participation was almost complete, with more than
99% of patients agreeing to enter the study. In Septem-
ber 2018, in the frame of this study, the Cluster Project
collected additional information from clinical records of
these patients, in order to investigate co-morbidities
present at the time of enrollment.
Non-AIDS/non-HIV co-morbidities considered in-
cluded: previous cardiovascular disease (pCVD), defined
as previous diagnosis of myocardial infarction, stroke,
angina pectoris, coronary artery, bypass grafting, angio-
plasty; diabetes mellitus, diagnosed with laboratory data
and drug-tracing criteria [13]; high blood pressure,
diagnosed with blood pressure measurement and drug-
tracing criteria [14]; history of non-AIDS defining
cancers, based on medical history, oncologic follow up
and drug-tracing criteria; osteoporosis, based on bone
density scan and drug-tracing criteria; clinical probable
chronic obstructive pulmonary disease (COPD), based
on the presence of at least 3 criteria among current
smoking habit, age > 40 years, chronic cough, sputum
production and dyspnea [15]; antibodies for hepatitis C
(HCV Ab+) coinfection; psychiatric illness, based on
medical history, specialist evaluation and drug-tracing
criteria; kidney disease, based on estimated glomerular
filtration rate (eGFR) < 60ml/min, calculated according to
the Modification of Diet in Renal Disease formula [16];
dyslipidemia, based on serum cholesterol (> 200mg/dL)
and triglycerides (> 150 g/dL) values and drug-tracing
criteria [17].
Multi-morbidity was defined as the presence of two or
more co-morbidities other than HIV infection. The
criterion of two or more chronic conditions has been
considered a cut-off score to compare multi-morbid and
non multi-morbid groups.
All study participants provided informed consent to
participate in the parent study, which was approved by
the institutional ethics committee of the coordinating
center (July 2014).
The STOPSHIV Study aimed at enrolling 1000 sub-
jects. In the Cluster Project, this sample size was consid-
ered adequate in order to obtain a precision of at least
5% for any morbidity with prevalence ranging from 10
to 90%.
Statistical methods. Continuous data are presented as
means (and standard deviation, SD), or medians (and
interquartile range, IQR), and categorical data as fre-
quency and proportions (%). We compared continuous
data using analysis of variance test or Wilcoxon test and
categorical data using chi-square statistics. Association
between risk factors and multi-morbidity was assessed
using the odds ratios (OR) and corresponding 95%
Confidence intervals (CI), including in the unconditional
logistic regression terms for age and sex. If a variable
had less than 5% of missing value they were not included
in the analysis. No information was missing in more
than 5% of subjects.
We assumed a significance level at a p-value < 0.05.
All statistical analyses were conducted using SAS 9.4
(SAS Institute, Inc., Cary, North Carolina).
Results
A total of 1087 patients have been enrolled. 799 (73.5%)
were men (mean age 48.6 ± SD 11.1), 288 (26.5%)
women (46.0 ± 9.6); overall mean age was 47.9 ± 10.8.
Patients were mainly Caucasians (89.2%); the main risk
factor for HIV acquisition was heterosexual intercourse
(44.7%). Other demographics are shown in Table 1.
One hundred-ninety patients (17.5%) had no co-
morbidity, whereas 285 (26.2%) had one condition and
612 (56.3%) were multi-morbid: 25.3% had two co-
morbidities, 19.3% three, 8.2% four,3.5% five or more. The
most frequent co-morbidity was dyslipidemia (55.3%),
followed by hypertension (31.4%), COPD (29.4%), hepatitis
C virus (HCV) infection (25.4, 5.5% with detectable
HCVRNA), psychiatric illness (10.3%), diagnosis of
osteopenia/osteoporosis (10.1%), diabetes (6.1%), and
renal impairment (4.8%); 95 (8.7%) subjects had history of
non-AIDS-defining cancer. Forty-nine patients (4.5%) had
pCVD events. Distribution of comorbidities by age class is
shown in Fig. 1.
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Analyzing the pairs of co-morbidities, the most recur-
rent associations were: 1) dyslipidemia + hypertension
(237, 21.8%); 2) dyslipidemia + COPD (188, 17.3%); 3)
COPD + HCV-Ab+ (141, 12.9%). Other frequent associ-
ations are shown in Fig. 2.
When we compared parameters of HIV infections and
patients’ characteristics between multi-morbid and non
multi-morbid patients, after adjusting for age and sex,
we observed that all variables were significantly related
with multi-morbidity status, except for CD4 cell count
used as a continuous variable (by 100 cells/mm3); being
ART naïve was not significantly different between
groups, although the proportion of ART naïve patients
was lower in the multi-morbid group (Table 2). Multi-
morbid patients were older and showed lower nadir
CD4 cell count, longer period in ART therapy, and, as
expected since these variables were used for comorbidity
definition, had higher triglycerides, glycemia, and total
cholesterol (Table 2). They were more frequently in
CDC stage B and C than in stage A. In a model includ-
ing age, sex, body mass index (BMI), cigarette smoking,
intravenous drug use (IVDU) as risk factor for HIV
acquisition, CDC stage, ART duration (by 2 years), and
current CD4 < 200 cells/mm3, multi-morbidity was
associated to CDC stage, years of ART, and current CD4
count < 200 cells/mm3. In the multivariable analysis,
type of ART regimen, whether based on protease inhibi-
tors (PI), non-nucleoside reverse transcriptase inhibitors
(NNRTI) or integrase strand transfer inhibitors (INSTI),
did not significantly differ between groups.
The main factors associated with multi-morbidity
were: age, BMI and smoking with CVD/COPD multi-
morbidity; age, smoking, and IVDU with CVD/HCV Ab;
smoking and CDC stage with CVD/psychiatric illness;
age and CDC stage with CVD/non-AIDS-defining
cancer; age, smoking, IVDU and CDC stage with CVD/
osteopenia or osteoporosis.
Recombining the co-morbidities in triads (Fig. 3), we
observed that the most recurrent ones were: 1) dyslipid-
emia + hypertension + COPD (71, 6.6%), significantly as-
sociated with age (aOR 1.06, 95% CI 1.03–1.09 by 1 year)
and BMI (aOR 1.10, 95% CI 1.04–1.16 by 1 point); 2)
dyslipidemia + COPD + HCV-Ab+ (69 patients, 6.3%),
more frequent in patients with longer ART duration
(aOR 1.18, 95% CI 1.08–1.28 by 2 years of treatment); 3)
hypertension + COPD + HCV-Ab+ (55, 5.1%), signifi-
cantly associated with sex (aOR 3.13, 95% CI 1.36–7.22)
and years of ART (aOR 1.20, 95% CI 1.10–1.32 by 2
years); 4) dyslipidemia + hypertension + HCV (53, 4.9%),
related to BMI (aOR 1.08, 95% CI 1.01–1.15), current
smoking (aOR 4.88, 95% CI 1.68–14.10) and ART dur-
ation (aOR 1.19, 95% CI 1.08–1.31 by 2 years).
We also had details on drug treatments for dyslipid-
emia and hypertension. Out of 601 subjects with dyslip-
idemia, 102 (17.0%) were on statins, and 58 (9.6%) on
other lipid-lowering drugs (some patients on both), thus
leaving 76.0% of subjects without treatment. Older
patients (≥65 years old) were more likely be treated than
younger ones (61.5% vs 20.4%, p < 0.0001). Similarly
though slightly better, out of 341 patients with high
blood pressure, 208 (61.0%) were on antihypertensive
drugs and 133 (39.0%) without treatment: 74.1% of
hypertensive subjects ≥65 years old were on treatment,
versus 58.5% of those aged less than 65 years (p = 0.03).
Table 1 Characteristics of 1087 patients enrolled in the Cluster
Project
Categorical variables





Current smoker 561 51.6




Heterosexual intercourse 486 44.7












Continuous variables Mean or median SD or IQR
Age (years) 47.9 10.8
BMI (Kg/m2) 24.7 4.1
Nadir CD4 (cells/mm3) 200.5 80.0–328.0
CD4 (cells/mm3) 634.0 430.0–824.0
Years since ART initiation 9.0 4.0–16.0
Serum creatinine (mg/dL) 0.92 0.63
Glycemia (mg/dL) 93.0 20.9
Total cholesterol (mg/dL) 186.1 41.5
Triglycerides (mg/dL) 118 84–178
eGFR (mL/min) 97.3 27.0
SD standard deviation, IQR interquartile range, MSM men having sex with men,
IVDU intravenous drug user, BMI body mass index, ART antiretroviral
treatment, eGFR estimated glomerular filtration rate
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Discussion
In our sample of patients attending the HIV-outpatient
facilities in the participating centers, we found that most
PLHW were multi-morbid and about 30% had three or
more concurrent conditions. Besides other known risk
factors, shared with the general population, such as age,
BMI and cigarette smoking, we found that CDC stage,
duration of ART and current CD4 cell count < 200 cells/
mm3 were risk factors for multi-morbidity.
As regards the frequency of two or more concurrent
medical conditions and their clusterization, data are
scarce and difficult to compare, at least partly because of
heterogeneous definitions of multi-morbidity [18, 19]. In
particular, few studies were performed among PLWH.
However, our findings are largely consistent with the re-
sults of recent studies [20–22].
In a cross-sectional study comparing 208 HIV positive
subjects with 208 matched HIV negative controls [20],
Fig. 1 Multi-morbidity prevalence by age categories. The following morbidity were included: CVD events, diabetes mellitus, hypertension,
dyslipidemia, HCV Ab+, psychiatric illness, osteopenia/osteoporosis, renal impairment
Fig. 2 Most frequent pairs of comorbidities
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the frequency of multi-morbidity was higher in the
former (63% vs 43%) than in the latter, and associated
with duration of HIV and ART. In our sample, multi-
morbid patients were about 54%, a lower proportion
likely due to the younger age of enrolled subjects, and
infection variables (duration of ART and advanced CDC
stage) were similarly linked to higher probability of
having 2 or more co-morbidities.
Comparing co-morbidity in a large cohort of veterans
with and without HIV infection, Goulet et al. [21] found
that co-morbidity was the rule (60% in HIV positive
veterans), and multi-morbidity was common among
those with HIV infection (10%). Patterns of comorbidity
differed substantially by HIV status, age, and HIV
severity. In multivariable analyses, older HIV-infected
veterans were more likely to have substance use disorder
and multi-morbidity.
Kim et al. [22] performed a study on a population of
PLWH, examining the relationship with obesity and
multi-morbidity. They found that prevalence increased
Table 2 Comparison of patients’ characteristics and parameters of HIV infections, between multi-morbid and non multi-morbid
patients. Adjusted odds ratios for risk of multi-morbidity
Multi-morbidity N = 612
(56.3%)
No multi-morbidity N = 475
(43.7%)
aOR 95% CI
Age, years, mean ± SD 51.7 ± 9.1 42.9 ± 10.7 1.08 (1.06–1.09) by 1 year
Women, N (%) 136 (22.2%) 152 (32.0%) 0.81 (0.58–1.15) ref. men
BMI, Kg/m2, mean ± SD 25.2 ± 4.6 24.0 ± 3.2 1.17 (1.07–1.16) by 1 point
Smoking, N (%)
Never 113 (18.5%) 204 (43.0%) 1
Current 265 (43.3%) 195 (41.0%) 3.65 (2.54–5.24)
Former 133 (21.7%) 76 (16.0%) 1.77 (1.14–2.75)
Risk factor for HIV acquisition IVDU 203 (33.2%) 37 (7.8%) 3.19 (2.02–5.04) ref. other risk factors
CDC stage, N (%)
A 229 (37.4%) 266 (56.0%) 1
B 177 (28.9%) 117 (24.6%) 1.20 (0.83–1.74)
C 195 (31.9%) 83 (17.5%) 2.04 (1.38–3.02)
ART duration, years, median (IQR) 12 (6–17) 6 (2–11) 1.08 (1.02–1.13) by 2 years
Current CD4, < 200 cells/mm3, N (%) 42 (6.9%) 23 (4.8%) 1.97 (1.01–3.87) ref. ≥200 cells/mm3
ART naïve, N (%) 14 (2.3%) 29 (6.1%) 1.32 (0.56–3.10) ref. experienced
Nadir CD4, cells/mm3, median (IQR) 170 (70–290) 242 (105–364) 1.00 (0.96–1.05) by 50 cells/ mm3
CD4, cells/mm3, median (IQR) 636 (434–852) 623 (425–780) 1.02 (0.97–1.08) by 100 cells/ mm3
Current PI, N* (%) 272 (44.4%) 169 (35.6%) 1.16 (0.84–1.59) ref. no PI
Current NNRTI, N* (%) 238 (38.9%) 172 (36.2%) 1.07 (0.78–1.47) ref. no NNRTI
Current INSTI, N* (%) 179 (29.2%) 108 (22.7) 1.22 (0.86–1.75) ref. no INSTI
N. of drugs in ART regimen
0 27 (4.4%) 56 (11.8%) ref.
1 24 (3.9%) 40 (8.4%) 0.72 (0.28–1.82)
2 89 (14.5%) 38 (8.0%) 1.72 (0.76–3.93)
3 447 (73.0%) 323 (68.0%) 1.24 (0.63–2.44)
>=4 25 (4.1%) 18 (3.8%) 1.33 (0.50–3.53)
χ2 for trend p = 0.39
Glycemia, mg/dL, mean ± SD 96.3 ± 25.3 88.8 ± 12.0 1.06 (1.01–1.12) by 5 mg/dL
Total cholesterol, mg/dL, mean ± SD 192.2 ± 42.9 178.3 ± 38.2 1.05 (1.03–1.08) by 5 mg/dL
Triglycerides, mg/dL, median (IQR) 146 (98–201) 96 (70–128) 1.08 (1.05–1.10) by 10 mg/dL
SD standard deviation, IQR interquartile range, aOR adjusted odds ratio, CI confidence interval, BMI body mass index, IVDU past intravenous drug use, ART
antiretroviral treatment; all variables are adjusted (as appropriate) for age (continuous variable), sex, BMI (continuous variable), cigarette smoking, IVDU, CDC
stage, ART duration (by 2 years), current CD4 count (< 200 cells/mm3), except for naïve status, that was only adjusted for age, sex, BMI, smoking habit, current CD4
cells count, and current CD4 count as a continuous variable, that was adjusted for age (continuous variable), sex, BMI (continuous variable), cigarette smoking,
IVDU, CDC stage, and ART duration (by 2 years)
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with progressive BMI categories. Three multi-morbidity
clusters were identified: “Metabolic”; “Behavioral”; and
“Substance Use”. Obesity was associated with a higher
likelihood of multi-morbidity: consistently, our findings
show a higher prevalence of multi-morbidity with higher
BMI, even after accounting for potential confounders:
this result was led by the positive association between
BMI and diabetes, hypertension and dyslipidemia, even
if a significant inverse relationship was observed with
HCV and osteopenia/osteoporosis.
In Italy, comorbidity prevalence has been evaluated by
Guaraldi et al. [23] in a sample of 2854 PLWH: using
similar diagnostic criteria, previous CVD event and renal
impairment prevalence estimates were largely similar,
but we found a much lower proportion of subjects with
diabetes (6.1% versus 11.1%) and a higher proportion of
hypertensive patients (31.4% versus 22.2%). In our study
as well as in Guaraldi et al.’s, age was the main deter-
minant of multi-morbidity, although we did not find a
significant detrimental role of being male. This discrep-
ancy may be due to the inclusion of smoking and past
IVDU in our analysis: in our sample, both factors were
more frequent in men than in women, and had a signifi-
cant relationship with multi-morbidity. Multi-morbidity
prevalence could not be compared between studies as
reported, because it depended on considered diseases:
however, if we defined multi-morbidity as Guaraldi et al.
did, just considering diabetes, bone diseases (although
with different definition), renal impairment and hyperten-
sion, our prevalence estimate was similar (about 14%).
In Geriatric HIV patients older than 65 years from
Italy (GEPPO cohort) multi-morbidity was largely
present (64% of cases) [24]. Although patients older than
65 years represented only a small proportion (6.3%) of
our sample, we consistently found that multi-morbidity
was present in about 76.7% of cases (56/73). Also, we
observed that in this subgroup drug treatment for hyper-
tension and dyslipidemia was more frequent than in
younger PLWH, probably because the concern for CVD
risk overrode the risk of drug-drug interaction, in clini-
cians’ opinion.
In a recent paper, comorbidities were assessed in
PLWH participating in two independent cohorts:
POPPY and AGEhIV [12]. Analysis identified 6 patterns
among the 1073 POPPY: CVD, sexually transmitted
diseases, mental health problems, cancers, metabolic
disorders, chest/other infections. The CVD pattern was
positively associated with cancer, while the mental health
Fig. 3 Most frequent triads of comorbidities
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pattern was correlated with all the other patterns In the
598 AGEhIV 6 patterns were identified: CVDs, chest/
liver, HIV/AIDS events, mental health/neurological
problems, STDs, and general health. The general health
pattern was correlated with all the other patterns.
Interestingly, Markun et al. [25] performed a study, in-
cluding HIV negative subjects, with the aim to identify
therapeutic conflicts in emergency department patients
with multi-morbidity. In this paper, major therapeutic
conflict was defined as a situation where clinical practice
guidelines recommended a treatment of a medical
condition, that is absolutely contraindicated because of a
coexisting condition (for example, a situation where
anticoagulation is recommended because of a pulmonary
embolism, but at the same time contraindicated because
of a co-existing gastrointestinal bleeding). Minor thera-
peutic conflict was defined as a situation where clinical
practice guidelines recommended a treatment of one
medical condition, that is relatively contraindicated
because of a co-existing condition, but the treatment is
possible without adverse effects if certain precautions
are taken (for example, a situation where acetylsalicylic
acid is recommended because of a vascular disease, but
at the same time contraindicated because of a co-
existing reflux esophagitis). Among major conflicts they
found: cancer requiring chemotherapy or immunosup-
pression in patients with renal failure, or with cirrhosis
at risk of gastrointestinal bleeding; and CVD requiring
acetylsalicylic acid or oral anticoagulants in cirrhotic
patients with disturbances of coagulation. Among minor
conflicts they found: CVD requiring diuretic treatment
in patients with renal failure; CVD requiring antihyper-
tensive agents in patients with renal failure or with
cirrhosis at risk of gastrointestinal bleeding; CVD in pa-
tients requiring beta blockers in patients with asthma.
Most of these disease-disease interactions are not infre-
quent in PLWH, but we are not aware of similar studies
among these patients.
We also had information on drug treatment for hyper-
tension and dyslipidemia. In both cases, we noted that
these conditions were undertreated, with about 25% of
dyslipidemic patients on any lipid-lowering treatments,
and 60% of hypertensive subjects on hypotensive drugs,
as already observed in samples of Italian patients [26, 27].
These two conditions were part of the most frequent
triads of non-AIDS/non-HIV related conditions observed
in our study, and as such they remained mostly untreated.
This finding may be related both to patients’ reluctance to
take other drugs, being subjects to a substantial pill
burden for HIV, and to physicians’ concern of potential
drug-drug interactions, in the context of the chronic
treatment for HIV infection.
Our data evidence that, in spite of mean age lower
than 50, co-morbidity was the rule among our PLWH
(82%), and that more than 50% of our patients were
multi-morbid. Moreover, about 30% of them had three
or more chronic non-HIV related conditions, thus
confirming recent data provided by other studies in the
field [8]. Dyslipidemia was, by far, the most frequent co-
morbidity, but potential HCV-related damage is still a
concern, mainly in patients with long-lasting co-
infection, despite the big efforts under way to cure this
condition. In the light of the study of Markun et al. [25],
the chronic conditions that appear most at risk for
disease-disease interactions are liver disease, renal im-
pairment and cardiovascular diseases. In our experience,
both in pairs and in triads they appear frequently associ-
ated with other comorbidities, and among them. All the
conditions potentially at risk for major and minor
disease-disease interactions suggested by Markun [22]
(respectively cancer + renal impairment, cancer + liver
disease, CVD + liver disease, and CVD + renal impair-
ment, CVD + liver disease, CVD + COPD) were present
among our patients, although in different percentages.
Not unexpectedly, multi-morbid patients presented
higher mean age, worse parameters of HIV infections,
more compromised metabolic data and renal function
with respect to non multi-morbid ones.
In our study we found that cigarette smoking, a
modifiable risk factor, was significantly associated with
multi-morbidity. This lifestyle factor is linked to increased
morbidity and mortality for both HIV and non-HIV
related diseases: tobacco use and HIV together may accel-
erate the development of chronic obstructive pulmonary
disease, lung cancer and death [28, 29], and smoking
resulted associated with a higher risk of myocardial infarc-
tion in the HIV-infected than in the general population as
well [30]. Our findings emphasize the need of smoking
cessation strategy, with the expectation of longer life
expectancy and better quality of life.
The main limitation of our study is the absence of a
control group of HIV-negative subject. Moreover, the
investigation aimed at identifying only the potential
disease-disease interactions; in particular, we considered
all the HCVAb+ patients, regardless of the level of liver
decompensation. Similarly, we considered also risk
factors for CVD, not only the presence of overt cardiac
disease. Even if our objective was not to examine poly-
pharmacy, a further challenge should be to evaluate the
impact of disease-disease interactions on polypharmacy
and, consequently, on drug-drug interactions. Few stud-
ies address the problem of clusterization of chronic non
communicable conditions among PLWH and, although
other cohorts examined a higher number of patients
respect to our experience, data were extracted from
diagnosis codes, like ICD-9-CM [21], or from electronic
health records [22]. In our study, data were provided by
the infectious disease specialists who followed their
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patients, thus providing more reliable and updated data.
As a main strength of this study, we could account for
several factors potentially related to multi-morbidity,
among infection variables, patients’ characteristics and
lifestyle factors, primarily smoking habit.
Conclusions
Considering the aging of PLWH, their persistent expos-
ure to chronic inflammation and the possible effects of
HAART, it is mandatory to address the phenomenon of
clusterization timely, and to detect all the patients at risk
of disease-disease interactions. The evaluation of com-
mon patterns of comorbidities in PLWH may help to
identify and address the combined risks of major and
minor therapeutic conflicts and their potential impact
on adverse effects and drug-drug interactions, as we
previously evidenced and exemplified. Moreover, this
should help to adequate the clinical practice guidelines
recommendation to this important example on how the
“medicine of complexities” is rapidly emerging in our
daily clinical practice.
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